| 초록 |
During the past several decades, in-stent restenosis and thrombosis have been still major reasons of clinical failure in the stent treatment for coronary artery diseases. Although drug-eluting stent (DES) has markedly reduced the restenosis rate as compared to bare metal stent (BMS), late thrombosis is still problem in DES. In addition, fully bioresorbable stent is recently emerging as an alternative to existing DES. However, several drawbacks such as inflammation and weak mechanical property still remain to be solved. The fundamental solution of such failures is well known to restore damaged endothelium, named re-endothelialization. In our laboratory, we have focused on improving existing coronary stents and especially enhancing clinical efficacy and safety of DES, and will address a number of advanced polymeric technologies for the commercialization of stents. |
